federal_register: 2018-27433

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts
2018-27433 Breakthrough Devices Program; Guidance for Industry and Food and Drug Administration Staff; Availability Notice The Food and Drug Administration (FDA or Agency) is announcing the availability of the final guidance entitled "Breakthrough Devices Program; Guidance for Industry and Food and Drug Administration Staff." This guidance document describes policies that FDA intends to use to implement the new Breakthrough Devices Program, established by the 21st Century Cures Act (Cures Act). The Breakthrough Devices Program supersedes and combines elements from FDA's Expedited Access Pathway (EAP), which was intended to facilitate the development and expedite review of certain devices that demonstrate the potential to address unmet medical needs, as well as the Priority Review Program, which implemented statutory criteria for granting priority review to premarket approval applications (PMAs) and applied those criteria to other types of premarket submissions for medical devices. This guidance is intended to clarify certain principles and features of the new program, the designation criteria for Breakthrough Devices, the designation request review process, the process for withdrawing from the program, as well as the recommended information device manufacturers should provide in their designation request for entrance into the program. 2018-12-19 2018 12 https://www.federalregister.gov/documents/2018/12/19/2018-27433/breakthrough-devices-program-guidance-for-industry-and-food-and-drug-administration-staff https://www.govinfo.gov/content/pkg/FR-2018-12-19/pdf/2018-27433.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA or Agency) is announcing the availability of the final guidance entitled "Breakthrough Devices Program; Guidance for Industry and Food and Drug Administration Staff." This guidance document describes policies that...

Links from other tables